PALISADE BIO, INC.

PALI · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
446
SEC Filings

Business Summary

. Company Overview We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohns disease (CD). Our Strategy We are committed to advancing a next generation of once daily, ...

Next Earnings

Q2 FY2026 — expected 2026-09-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPALIdiscussed_in_filing Cybersecurity
topic_mentionPALIdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-202025-12-310001357459-26-000004EDGAR76K words
2025-03-242024-12-310000950170-25-043859EDGAR—
2024-03-262023-12-310000950170-24-036402EDGAR—
2023-03-222022-12-310000950170-23-009226EDGAR—
2022-03-172021-12-310000950170-22-004093EDGAR—
2021-03-222020-12-310001171843-21-001965EDGAR—
2020-03-272019-12-310001171843-20-002061EDGAR—
2019-03-222018-12-310001171843-19-001917EDGAR—
2018-04-022017-12-310001171843-18-002404EDGAR—
2017-03-232016-12-310001171843-17-001704EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-274262EDGAR39K words
2025-08-112025-06-300000950170-25-106587EDGAR—
2025-05-122025-03-310000950170-25-069204EDGAR—
2024-11-122024-09-300000950170-24-124664EDGAR—
2024-08-122024-06-300000950170-24-095432EDGAR—
2024-05-132024-03-310000950170-24-058644EDGAR—
2023-11-092023-09-300000950170-23-062215EDGAR—
2023-08-102023-06-300000950170-23-041459EDGAR—
2023-05-112023-03-310000950170-23-021374EDGAR—
2022-11-142022-09-300000950170-22-024748EDGAR—
2022-08-152022-06-300000950170-22-017248EDGAR—
2022-05-132022-03-310000950170-22-009812EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001493152-26-014822EDGAR1K words
2025-12-040001493152-25-026195EDGAR—
2025-10-220001493152-25-018922EDGAR—
2025-10-200001493152-25-018684EDGAR—
2025-10-160001493152-25-018324EDGAR—
2025-10-090001493152-25-017630EDGAR—
2025-09-260001493152-25-015775EDGAR—
2025-09-180001493152-25-014071EDGAR—
2025-09-050001493152-25-012687EDGAR—
2025-07-250001641172-25-020896EDGAR—

446 total filings indexed. 414 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001357459
TickerPALI
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 4d6b45cb667be8b47bebeac3391413e2570d9fff150e8b0f6db44607130b3af6
parent: 2e935f17acb5612cf7851c6e024273f48868a543bdd58114d3ec4a2a08f094a1
content hash: 3f5c8b31af03b1f309c17ce2b1618c0c75821a962a851465e56dc6c7f74a43e9
signed: 2026-04-13T04:46:48.317Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf